Bringing the fundamentals into focus…
Back to Monte Rosa Therapeutics, Inc.
How Monte Rosa Therapeutics, Inc. stacks up
GLUE · against 486 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #326 of 487 · scores higher than 10% of peers
Bars: peers in each 10-point band of the valuation score162 peers with a valuation score of 0–9, including GLUE · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -57.0% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -18.1% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -3.6% vs peer median 0.0%
Metric by metric
Position: dot = GLUE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | GLUE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 475 reported | -16.8% | 1.1% | 12% | 30% | |
| EBITDA yieldHigher is better · 493 reported | -57.0% | 4.1% | 2% | 50% | |
| Free cash flow yieldHigher is better · 211 reported | -3.6% | -2.7% | 48% | 20% | |
| Book yieldHigher is better · 483 reported | 54.9% | 41.9% | 64% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around GLUE| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 326 | 660M USD | 8 | 43 | |
| 326 | 533M USD | 8 | 36 | |
| 326 | 598M USD | 8 | 49 | |
| 326 | 1.4B USD | 8 | 38 | |
| 326 | 888M USD | 8 | 25 | |
| 326 | 1.5B USD | 8 | 44 | |
| 326 | 471M USD | 8 | 21 | |
| 326 | 660M USD | 8 | ||
| 326 | 1.1B USD | 8 | 32 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score